A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2

Abstract

In clinical routine pathology today, detection of protein in intact formalin-fixed, paraffin-embedded tissue is limited to immunohistochemistry, which is semi-quantitative. This study presents a new and reliable quantitative immunohistochemistry method, qIHC, based on a novel amplification system that enables quantification of protein directly in formalin-fixed, paraffin-embedded tissue by counting of dots. The qIHC technology can be combined with standard immunohistochemistry, and assessed using standard bright-field microscopy or image analysis. The objective was to study analytical performance of the qIHC method. qIHC was tested under requirements for an analytical quantitative test, and compared with ELISA and flow cytometry for quantitative protein measurements. Human epidermal growth factor receptor 2 (HER2) protein expression was measured in five different cell lines with HER2 expression from undetectable with immunohistochemistry to strong positive staining (IHC 3+). Repeatability, reproducibility, robustness, linearity, dynamic range, sensitivity, and quantification limits were evaluated. Reproducibility and robustness were assessed in a setup to resemble daily work in a laboratory using a commercial immunohistochemistry platform. In addition, qIHC was correlated to standard HER2 immunohistochemistry in 44 breast cancer specimens. For all evaluated parameters, qIHC performance was either comparable or better than the reference methods. Furthermore, qIHC has a lower limit of detection than both immunohistochemistry and the ELISA reference method, and demonstrated ability to measure HER2 accurately and precise within a large dynamic range. In conclusion, the results show that qIHC provides a sensitive, quantitative, accurate, and robust assay for measurement of protein expression in formalin-fixed, paraffin-embedded cell lines, and tissue.

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

“…3b.). Sensitivity was demonstrated by calculating a signal to noise (S/N) ratio using the criterion for detection capability in clinical laboratories proposed by CLSI EP17-A2 [30], which we adopted for PID to include the limit of detection requirement of (S/N) ratio above 3 and limit of quantification (S/N) ratio above 10. In this study, PID HER2 expression level of the MCF7 cell line was the limit of detection and the T47D cell line was the limit of quantification and, although the MCF 7 and T47D are defined as a score of 0 in the IHC-DAB method, it fell within the detection capacity of the PID method (Fig.…”

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases

“…Quantification of ERBB2 copy number and HER2 protein expression by analyses such as quantitative IHC ( Jensen et al 2017 ), PCR, FISH, and protein mass spectrometry has a potential advantage over nonquantitative or semiquantitative detection of HER2 positivity. Data from the HERACLES trial suggested that higher levels of ERBB2 amplification are associated with an increased likelihood of response to HER2-directed therapy in CRC ( Sartore-Bianchi et al 2016 ).…”

Water-Soluble Pristine C60 Fullerene Inhibits Liver Alterations Associated with Hepatocellular Carcinoma in Rat

“…The staining intensity of the cells was assessed using the following scoring: 0—negative, 1—weak; 2—moderate; 3—strong. Histo-score (H-score) was calculated as follows: H-score = 1 × %% weakly stained cells + 2 × %% moderately stained cells + 3 × %% strongly stained cells [ 17 ].…”